2016 Undergraduate Summer Research Program Participant

Home Department: Bioengineering
Supported by: Bio-X
Mentors: Calvin Kuo, Medicine (Hematology); and Stanley Qi, Bioengineering and Chemical & Systems Biology

To advance the development of cancer treatments, The Cancer Genome Atlas (TCGA) has carried out genome scale DNA sequencing efforts of a variety of cancers to identify novel druggable targets; however, these data require functional validation in a biological system. Daniel Hart will use the CRISPR/Cas9 system for genetic screens in primary organoid culture to identify key drug targets in esophageal cancer by conducting loss of function and gain of function screens.

Poster presented at the Stanford Bio-X Interdisciplinary Initiatives Symposium on August 24, 2016:

Engineering Screening Approaches to Validate Cancer Driver Genes

Daniel Hart1, Sean de la O1, Antonia Dominguez2, Ameen Salahudeen1, Stanley Qi2, Calvin Kuo1
[Departments of Medicine (Division of Hematology)1 and Bioengineering2, Stanford University]